Pretreatment of normal responders in fresh in vitro fertilization cycles: A comparison of transdermal estradiol and oral contraceptive pills.
10.5653/cerm.2016.43.4.228
- Author:
Nigel PEREIRA
1
;
Allison C PETRINI
;
Zhen N ZHOU
;
Jovana P LEKOVICH
;
Isaac KLIGMAN
;
Zev ROSENWAKS
Author Information
1. Ronald O. Perelman and Claudia Cohen Center for Reproductive Medicine, Weill Cornell Medical Center, New York, NY, USA. nip9060@med.cornell.edu
- Publication Type:Original Article
- Keywords:
Contraceptives, Oral, Combined;
In vitro fertilization;
Reproductive techniques, Assisted;
Superovulation;
Transdermal patch
- MeSH:
Abortion, Spontaneous;
Cohort Studies;
Contraceptives, Oral, Combined;
Estradiol*;
Female;
Fertilization in Vitro*;
Gonadotropins;
Humans;
In Vitro Techniques*;
Live Birth;
Oocytes;
Ovulation Induction;
Pregnancy;
Pregnancy Outcome;
Reproductive Techniques, Assisted;
Retrospective Studies;
Superovulation;
Transdermal Patch
- From:Clinical and Experimental Reproductive Medicine
2016;43(4):228-232
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVE: The aim of this study was to investigate the impact of pretreatment with transdermal estradiol (E₂) compared to oral contraceptive pills (OCPs) on controlled ovarian stimulation (COS) response in normal responders undergoing fresh in vitro fertilization (IVF)-embryo transfer (ET) cycles. METHODS: A retrospective cohort study was performed of normal responders undergoing fresh IVF-ET cycles who received pretreatment with transdermal E₂ versus OCPs prior to fresh IVF-ET. The total days of ovarian stimulation, total dosage of gonadotropins, total number of oocytes, and mature oocytes retrieved were noted. Pregnancy outcomes after ET were also recorded. RESULTS: A total of 2,092 patients met the inclusion criteria: 1,057 and 1,035 patients in the transdermal E₂ and OCP groups, respectively. Patients in the OCP group had a longer duration of COS (10.7±1.63 days, p<0.01) than the E₂ group (9.92±1.94 days). Patients in the OCP group also required higher cumulative doses of gonadotropins (2,657.3±1,187.9 IU) than those in the E₂ group (2,550.1±1,270.2 IU, p=0.002). No statistically significant differences were found in the total and mature oocytes retrieved or in the rates of biochemical pregnancy, clinical pregnancy, spontaneous miscarriage, and live birth between the groups. CONCLUSION: Our findings suggest that compared to OCPs, pretreatment with transdermal E₂ is associated with a shorter duration of ovarian stimulation and lower gonadotropin utilization, without compromising the oocyte yield or pregnancy outcomes in normal-responder patients undergoing fresh IVF.
